Mother could give birth to her own GRANDCHILD
Jasmine Bowley, 21, from Norwich, had her ovaries and Fallopian tubes removed when she developed pelvic Ewing's sarcoma aged seven - which also affected her womb. (Source: the Mail online | Health)
Source: the Mail online | Health - February 18, 2020 Category: Consumer Health News Source Type: news

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
In this study at UCLA, a national leader in the care of patients with sarcoma, researchers used a condensed five-day radiation regimen that considerably cuts down the length of treatment and the time to surgery.“Shortening the radiation therapy from five weeks to five days has been a very meaningful change for patients,” said lead author Dr. Anusha Kalbasi, assistant professor of radiation oncology in the division of molecular and cellular oncology. “Five weeks of daily treatments is a burdensome com mitment for patients. The daily back-and-forth can be expensive and time consuming, and it can really inte...
Source: UCLA Newsroom: Health Sciences - February 13, 2020 Category: Universities & Medical Training Source Type: news

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
(University of California - Los Angeles Health Sciences) A new study led by researchers at UCLA found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news

UN Health Agency Predicts 80 Percent Rise in Cancer Burden Among Poorest Countries
Many specialist doctors and nurses in Africa are migrating to greener pastures, leaving cancer patients with few options. Credit: Jeffrey Moyo/IPSBy External SourceLONDON, Feb 7 2020 (IPS) Low- and middle-income countries could see an 80 per cent rise in cancer over the next 20 years if treatment and prevention services are not stepped up, according to the latest World Cancer Report. The report, compiled by the World Health Organization (WHO), warns that cancer prevention is taking a back seat in poor countries, as their health systems tackle such immediate problems as infectious diseases, child health and nutrition. The r...
Source: IPS Inter Press Service - Health - February 7, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health Poverty & SDGs Source Type: news

St. Jude's scientist receives ACGT grant for sarcoma gene therapy
(Alliance for Cancer Gene Therapy) Stephen Gottschalk, MD, of St. Jude Children's Research Hospital receives $500k grant to use genetically engineered immune cells to attack pediatric sarcoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2020 Category: Cancer & Oncology Source Type: news

Drug Trials Snapshots: TAZVERIK
TAZVERIK is a drug used to treat a type of cancer called advanced epithelioid sarcoma. It is to be used in patients 16 years and older when cancer has spread and cannot be completely removed by surgery. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Entrepreneur Leila Janah died from complications of epithelioid sarcoma. Here's what that is
Leila Janah, a fierce entrepreneur who worked to help those living below the poverty line, died in January from complications of epithelioid sarcoma -- a form of cancer. (Source: CNN.com - Health)
Source: CNN.com - Health - February 2, 2020 Category: Consumer Health News Source Type: news

Treatment Combination May Be Effective for Antitumor Activity in Advanced Sarcoma
The combination of talimogene laherparepvec and pembrolizumab was associated with antitumor activity across a range of sarcoma histologic subtypes in this phase II clinical trial. (Source: CancerNetwork)
Source: CancerNetwork - January 28, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
Title: Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid SarcomaCategory: Health NewsCreated: 1/24/2020 12:00:00 AMLast Editorial Review: 1/27/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 27, 2020 Category: Cancer & Oncology Source Type: news

Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
Approval marks the first for a drug to treat this rare soft tissue sarcoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 25, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
FRIDAY, Jan. 24, 2020 -- Tazverik (tazemetostat) has received the first approval for treatment of adults and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that cannot be resected, the U.S. Food and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 24, 2020 Category: General Medicine Source Type: news

FDA approves tazemetostat for advanced epithelioid sarcoma
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Tazemetostat (Tazverik) for Rare Sarcoma FDA Approves Tazemetostat (Tazverik) for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Tazemetostat (Tazvenik) for Rare Sarcoma FDA Approves Tazemetostat (Tazvenik) for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Tazemetostat, First Drug for Rare Sarcoma FDA Approves Tazemetostat, First Drug for Rare Sarcoma
The drug has a novel mechanism of action and is the first to be approved for use in epithelial sarcoma, which is rare but life-threatening.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves first treatment option specifically for patients with epithelioid sarcoma
Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ). (Source: World Pharma News)
Source: World Pharma News - January 24, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Tazemetostat for the Treatment of Epithelioid Sarcoma
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the methyltransferase inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA approves local biotech's first rare-cancer drug
The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc. Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the drug, Tazverik, to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer. Tazverik is the fi rst drug specifically designed for the cancer, which is diagnosed in 150 to 200 people each year, according… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 24, 2020 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

FDA approves local biotech's first rare-cancer drug
The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc. Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the drug, Tazverik, to treat metastatic or locally advanced epitheliod sarcoma, a rare and aggressive form of soft tissue cancer. Tazverik is the fi rst drug specifically designed for the cancer, which is diagnosed in 150 to 200 people each year, according… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 24, 2020 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 23, 2020-- Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 23, 2020 Category: Drugs & Pharmacology Source Type: news

B cells: New allies in sarcoma immunotherapy?
(INSERM (Institut national de la sant é et de la recherche m é dicale)) How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer? An international team led by Wolf Herv é Fridman with researchers from Inserm, Sorbonne Universit é and Universit é de Paris, has shown that B cells also play a major role in predicting of patient's response to immunotherapy. Their findings, to be published in Nature, pave the way for the personalization of treatments for patients with soft tissue sarcomas. (Source: EurekAlert! ...
Source: EurekAlert! - Medicine and Health - January 15, 2020 Category: International Medicine & Public Health Source Type: news

B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer
(University of Texas M. D. Anderson Cancer Center) Multiple studies out in Nature indicate that a patient's response to immune checkpoint blockade may depend on B cells located in special structures within the tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2020 Category: Cancer & Oncology Source Type: news

Public Insurance Tied to Lower Cancer Survival in Young Patients
FRIDAY, Dec. 27, 2019 -- Young, low-income patients with bone or soft tissue sarcomas have decreased overall survival (OS), regardless of disease stage at presentation, according to a study published online Dec. 15 in Cancer Medicine. Neela L.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2019 Category: Pharmaceuticals Source Type: news

Teenager with incurable cancer refuses to stop smiling despite spending Christmas in hospital
Joseph Lunn, from Mitcham, south London, was diagnosed with synovial sarcoma, a rare and incurable cancer in his abdomen. He had four tumours removed over Christmas. (Source: the Mail online | Health)
Source: the Mail online | Health - December 27, 2019 Category: Consumer Health News Source Type: news

Combination of chemo and diabetes drugs shows potential for treating Ewing sarcoma
(Houston Methodist) Houston Methodist researchers propose a combination of two well-known drugs as a new treatment option for Ewing sarcoma -- one of them typically used to treat diabetes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2019 Category: Cancer & Oncology Source Type: news

SP-2577 Granted Fast Track Designation by the FDA for Patients with Ewing Sarcoma
The drug is currently the subject of an ongoing phase I/II clinical study for the treatment of patients with Ewing sarcoma who have relapsed or are refractory to standard-of-care therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Medtech in a Minute: 3M Quits Drug-Delivery, New FDA Commissioner, and More
It's Official, Hahn Will Lead FDA The U.S. Senate voted 72-18 to confirm Stephen Hahn, MD, as the new FDA Commissioner. The news has been well received by industry advocacy groups like AdvaMed and professional societies like the American Heart Association. Hahn is a radiation oncologist who specializes in treating lung cancer and sarcoma.   3M Calls It Quits on Drug Delivery The company plans to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for $650 million plus a 17% noncontrolling interest...
Source: MDDI - December 13, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

It & #039;s Official, Hahn Will Lead FDA
FDA officially has a new boss. The U.S. Senate voted 72-18 on Thursday to confirm Stephen Hahn, MD, as the new FDA Commissioner. The news was largely well received by industry advocacy groups like AdvaMed and professional societies like the American Heart Association. “Dr. Hahn is an excellent choice to lead FDA, and we congratulate him on his swift and overwhelming bipartisan confirmation," said AdvaMed CEO Scott Whitaker. "During the confirmation process, Dr. Hahn demonstrated his deep understanding of the agency’s mission to pr...
Source: MDDI - December 13, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

Adaptimmune gets FDA designation to accelerate development of cancer therapy
The Food and Drug Administration has awarded a key designation to a therapy Adaptimmune is developing for a rare type of cancer. Adaptimmune's experimental T-cell therapy, called ADP-A2M4, targets synovial sarcoma, a cancer that occurs primarily in the extremities of the arms or legs. About two people out of every one million are diagnosed with the condition annually. The FDA designated ADP-42M4 as a regenerative medicine advanced therapy. That designation, established as part of the 21st Century… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 3, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

Markedly Elevated Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Markedly Elevated Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma
The risk of bone and soft-tissue sarcoma is markedly elevated in long-term survivors of hereditary retinoblastoma treated with radiation, researchers report.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 26, 2019 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

Turning key metabolic process back on could make sarcoma more susceptible to treatment
(University of Pennsylvania School of Medicine) Soft tissue sarcoma cells stop a key metabolic process which allows them to multiply and spread, and so restarting that process could leave these cancers vulnerable to a variety of treatments (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 26, 2019 Category: Biology Source Type: news

Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast
This case suggests that breast sarcomas could be treated in the same way as other soft tissue sarcomas in terms of adjuvant chemotherapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Day-glo dye helps surgeons to trace the trickiest tumours
British doctors are using the substance to help identify a type of cancer called sarcomas, which affect thousands every year. The new technique could spare some patients limb amputations. (Source: the Mail online | Health)
Source: the Mail online | Health - November 16, 2019 Category: Consumer Health News Source Type: news

Gene Editing Tool Fights Cancer in Early Study
So far, CRISPR has only been tried in three patients, two with multiple myeloma and one with a sarcoma. All had tried standard treatments, to no avail. (Source: WebMD Health)
Source: WebMD Health - November 7, 2019 Category: Consumer Health News Source Type: news

CRISPR-Edited T Cells Used in Cancer Patients for the First Time in the US
The initial findings from a small clinical trial of patients with multiple myeloma or sarcoma suggest that gene-edited immunotherapy is safe. (Source: The Scientist)
Source: The Scientist - November 6, 2019 Category: Science Tags: News & Opinion Source Type: news

Trump Nominates Stephen Hahn to Be the New FDA Commissioner
Stephen Hahn, a chief medical executive at the MD Anderson Cancer Center, has been tapped by President Trump to be the new FDA commissioner. The 59-year-old is a radiation oncologist that specializes in treating lung cancer and sarcoma. He has authored 220 peer-reviewed original research articles. AdvaMed was highly supportive of the decision giving Hahn praise. In a release, the device-advocacy agency said, “We congratulate Dr. Hahn on his nomination to lead FDA, and we hope the Senate moves swiftly to confirm him. Dr. Hahn’s distinguished career as a healthcare provider and researcher...
Source: MDDI - November 4, 2019 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news

Medical News Today: Ewing sarcoma: What to know
Ewing sarcoma is a rare form of bone cancer that most commonly affects children and teenagers. In this article, learn about the symptoms, causes, and treatment options. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 24, 2019 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Canon-Mac parents want deeper investigation of suspected childhood cancer cluster
Holding the funeral-home portrait of her son Curtis who died in 2011 from Ewing's sarcoma, Cindy Valent came to a hearing Monday night about the suspected cancer cluster in Washington County with a direct request: Find out why so many youth in southwestern Pennsylvania have contracted the rare and deadly form of cancer, and whether it has anything to do with the natural gas industry. Valent, who now lives in Beaver County, used to live in Cecil less than a mile from two other youth with Ewing's.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 8, 2019 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Canon-Mac parents want deeper investigation of suspected childhood cancer cluster
Holding the funeral-home portrait of her son Curtis who died in 2011 from Ewing's sarcoma, Cindy Valent came to a hearing Monday night about the suspected cancer cluster in Washington County with a direct request: Find out why so many youth in southwestern Pennsylvania have contracted the rare and deadly form of cancer, and whether it has anything to do with the natural gas industry. Valent, who now lives in Beaver County, used to live in Cecil less than a mile from two other youth with Ewing's.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 8, 2019 Category: Biotechnology Authors: Paul J. Gough Source Type: news

Hysterectomy Technique Tied to Poorer Uterine Cancer Outcomes
MONDAY, Oct. 7, 2019 -- Uncontained power morcellation is associated with a higher mortality risk in women with occult uterine sarcoma, especially in those with occult leiomyosarcoma, according to a study published online Sept. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 7, 2019 Category: Pharmaceuticals Source Type: news

Judge cancels court-ordered cancer surgery for girl, 13, after mom tried to treat her with CBD oil
An Oregon court canceled a surgery the state had ordered for Kylee Dixon, 13, of Wilsonville, to treat a rare liver cancer, undifferentiated embryonal sarcoma, which she was diagnosed with in 2018. (Source: the Mail online | Health)
Source: the Mail online | Health - September 27, 2019 Category: Consumer Health News Source Type: news

Texas boy, 10, battling a rare bone cancer walks just hours after having his leg amputated
Bryan Marquez, 10, from San Antonio, Texas, started having trouble walking and was limping. He was diagnosed this year with a rare bone cancer known as Ewing sarcoma. (Source: the Mail online | Health)
Source: the Mail online | Health - September 23, 2019 Category: Consumer Health News Source Type: news

Large-Defect Resurfacing: A Comparison of Skin Graft Results Large-Defect Resurfacing: A Comparison of Skin Graft Results
This study reports the clinical results of large skin grafts after sarcoma resection or traumatic injury repair.Wounds (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 11, 2019 Category: Surgery Tags: General Surgery Journal Article Source Type: news

Chest X-Ray Favored for Lung Surveillance After High-Grade Soft Tissue Sarcoma Chest X-Ray Favored for Lung Surveillance After High-Grade Soft Tissue Sarcoma
Chest x-ray may be better than chest CT for lung surveillance after resection of high-grade soft-tissue sarcoma, according to findings from the U.S. Sarcoma Collaborative (USSC).Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 4, 2019 Category: Radiology Tags: Hematology-Oncology News Source Type: news

New Hope for Advanced Sarcomas
New hope for advanced sarcomas Naveed Saleh, MD, MS (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

' Most Confusing' Desmoid Tumors: Pazopanib Now an Option?'Most Confusing' Desmoid Tumors: Pazopanib Now an Option?
Several treatment options have been described for desmoid tumors, but none is approved. Now the French Sarcoma Group is adding pazopanib to the list, but this is premature, says an expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 30, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 25, 2019-- Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 25, 2019 Category: Drugs & Pharmacology Source Type: news

Global Aids Fight Running out of Steam, U.N. says
BANGLADESH: Dose of Vigilance Helps Manage HIV, AIDS DHAKA, Nov 3, 2010 (IPS) - It is one of the poorest countries in the world, has a low literacy rate, and is next door to at least two countries that have a considerable portion of their respective populations with HIV and AIDS. Yet even having a large migrant population has not made Bangladesh a hot spot for HIV and AIDS. http://ipsnews.net/news.asp?idnews=53443By James ReinlUNITED NATIONS, Jul 24 2019 (IPS) The global fight against Aids is floundering amid cash shortfalls and spikes in new HIV infections among marginalised groups in developing regions, Gunilla Carlsson,...
Source: IPS Inter Press Service - Health - July 24, 2019 Category: International Medicine & Public Health Authors: James Reinl Tags: Development & Aid Featured Global Headlines Health IPS UN: Inside the Glasshouse Regional Categories TerraViva United Nations Joint United Nations Programme on HIV/AIDS (UNAIDS) Médecins Sans Frontières (MSF) Source Type: news

Researchers unveil experimental compound to block therapeutic target in blood cancer
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center researchers have discovered a hyperactive cell signal that contributes to tumor growth in primary effusion lymphoma, an aggressive type of non-Hodgkin lymphoma caused by infection with the Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). They also reported in the PNAS paper that they've developed an experimental therapeutic, UNC3810A, to block the signal and slow tumor growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2019 Category: Cancer & Oncology Source Type: news

Understanding sarcoma: from diagnosis to treatment
A cancer diagnosis can be scary and confusing, especially for a patient receiving a sarcoma diagnosis. What is sarcoma? Sarcoma is a rare cancer of the soft tissues and bone. Most types of cancer originate in the epithelial linings that cover exposed surfaces of the body and have direct exposure to environmental toxins. Sarcomas, however, originate from cells or tissues that lie below these lini ngs in the muscle, bone, cartilage, fat, blood vessels, smooth muscle and skeletal muscles. Any type… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 30, 2019 Category: Pharmaceuticals Authors: Dr. Kamal Ummed Source Type: news